Search

Displaying results 1581 - 1590 of 10000 in total
  1. Drug

    Amoxapine

    go.drugbank.com/drugs/DB00543
    Approved

    The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. … Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Adrenergic alpha-1 Receptor Antagonists
  2. Drug

    RG2417

    go.drugbank.com/drugs/DB05055
    Investigational

    Recent reports indicate that certain genes that encode for mitochondrial proteins are significantly down regulated in the brains of bipolar patients. … This new insight suggests that the symptoms of bipolar disorder may be linked to dysregulation of energy metabolism of the brain.

  3. Drug

    Paroxetine

    go.drugbank.com/drugs/DB00715
    ApprovedInvestigational

    [T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. … [A31914] The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    Aclidinium

    go.drugbank.com/drugs/DB08897
    Approved

    It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. … Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD).

    Categories: Agents to Treat Airway Disease
  5. Drug

    Iproniazid

    go.drugbank.com/drugs/DB04818
    ApprovedWithdrawn

    Withdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Metaxalone

    go.drugbank.com/drugs/DB00660
    ApprovedInvestigational

    Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. … It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous system depression.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Target

    Galectin-9

    go.drugbank.com/bio_entities/BE0004333
    TargetTransporterHumans

    Binds galactosides (PubMed:18005988). Has high affinity for the Forssman pentasaccharide (PubMed:18005988). Ligand for HAVCR2/TIM3 (PubMed:16286920). Binding to HAVCR2 induces T-helper type 1 lymphocyte (Th1) death (PubMed:16286920). Als...

    Synonyms: Tumor antigen HOM-HD-21
  8. Drug

    Dezocine

    go.drugbank.com/drugs/DB01209
    ApprovedInvestigational

    Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  9. Drug

    Chromium

    go.drugbank.com/drugs/DB11136
    ApprovedInvestigational

    Chromium is a transition element with the chemical symbol Cr and atomic number 24 that belongs to Group 6 of the periodic table. … in commercial settings and are known to be human carcinogens [L1982].

    Mixtures: Advanced B & T Formula, Mte 4 Inj
  10. Drug

    Sodium phosphate, monobasic

    go.drugbank.com/drugs/DB09449
    ApprovedInvestigational

    Sodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.

    Mixtures: Urimar-T, Urimar-T